Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ulrich Germing

Showing results (261-270 of 339) with videos related to

Pageof 34
Sort By:
Blood|January 28, 2015
An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adultsMichael R Savona, Luca Malcovati, Rami Komrokji, et al.
Annals of Hematology|November 25, 2015
Decitabine improves progression-free survival in older high-risk MDS patients with multiple autosomal monosomies: results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study GroupMichael Lübbert, Stefan Suciu, Anne Hagemeijer, et al.
Leukemia|March 25, 2018
Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: a European LeukemiaNet studyReinhard Stauder, Ge Yu, Karin A Koinig, et al.
European Journal of Haematology|May 17, 2021
Impact of age on the cumulative risk of transformation in patients with chronic myelomonocytic leukaemiaSigrid Machherndl-Spandl, Eva Jäger, Agnes Barna, et al.
Hemasphere|July 16, 2024
Refinement of the prognostic impact of somatic <i>CEBPA</i> bZIP domain mutations in acute myeloid leukemia: Results of the AML Study Group (AMLSG)Frank G Rücker, Andrea Corbacioglu, Julia Krzykalla, et al.
Genes, Chromosomes & Cancer|September 11, 2015
Frequency of del(12p) is commonly underestimated in myelodysplastic syndromes: Results from a German diagnostic study in comparison with an international control groupFriederike Braulke, Catharina Müller-Thomas, Katharina Götze, et al.
British Journal of Haematology|January 17, 2016
Myelodysplastic syndromes with single neutropenia or thrombocytopenia are rarely refractory cytopenias with unilineage dysplasia by World Health Organization 2008 criteria and have favourable prognosisEmmanuel Gyan, Valérie Andrieu, Alessandro Sanna, et al.
British Journal of Haematology|April 25, 2015
Validation of the revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registryLouise de Swart, Alex Smith, Thomas W Johnston, et al.
Annals of Hematology|April 27, 2021
Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q)Anna Hecht, Julia A Meyer, Johann-Christoph Jann, et al.
Blood Advances|January 6, 2023
Determinants of low health-related quality of life in patients with myelodysplastic syndromes: EUMDS Registry studyIgor Stojkov, Annette Conrads-Frank, Ursula Rochau, et al.
Pageof 34

Showing results (261-270 of 339) with videos related to

Sort By:
Pageof 34
Blood|January 28, 2015
An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adultsMichael R Savona, Luca Malcovati, Rami Komrokji, et al.
Annals of Hematology|November 25, 2015
Decitabine improves progression-free survival in older high-risk MDS patients with multiple autosomal monosomies: results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study GroupMichael Lübbert, Stefan Suciu, Anne Hagemeijer, et al.
Leukemia|March 25, 2018
Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: a European LeukemiaNet studyReinhard Stauder, Ge Yu, Karin A Koinig, et al.
European Journal of Haematology|May 17, 2021
Impact of age on the cumulative risk of transformation in patients with chronic myelomonocytic leukaemiaSigrid Machherndl-Spandl, Eva Jäger, Agnes Barna, et al.
Hemasphere|July 16, 2024
Refinement of the prognostic impact of somatic <i>CEBPA</i> bZIP domain mutations in acute myeloid leukemia: Results of the AML Study Group (AMLSG)Frank G Rücker, Andrea Corbacioglu, Julia Krzykalla, et al.
Genes, Chromosomes & Cancer|September 11, 2015
Frequency of del(12p) is commonly underestimated in myelodysplastic syndromes: Results from a German diagnostic study in comparison with an international control groupFriederike Braulke, Catharina Müller-Thomas, Katharina Götze, et al.
British Journal of Haematology|January 17, 2016
Myelodysplastic syndromes with single neutropenia or thrombocytopenia are rarely refractory cytopenias with unilineage dysplasia by World Health Organization 2008 criteria and have favourable prognosisEmmanuel Gyan, Valérie Andrieu, Alessandro Sanna, et al.
British Journal of Haematology|April 25, 2015
Validation of the revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registryLouise de Swart, Alex Smith, Thomas W Johnston, et al.
Annals of Hematology|April 27, 2021
Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q)Anna Hecht, Julia A Meyer, Johann-Christoph Jann, et al.
Blood Advances|January 6, 2023
Determinants of low health-related quality of life in patients with myelodysplastic syndromes: EUMDS Registry studyIgor Stojkov, Annette Conrads-Frank, Ursula Rochau, et al.
Pageof 34